

CUMULATIVE INDEX 1993

Volume 20

March	CURRENT CONTROVERSIES IN PERINATAL CARE II, pages 1-285
June	PERINATAL ASPHYXIA, pages 287-505
September	DIABETES IN PREGNANCY, pages 507-667
December	SURFACTANT REPLACEMENT THERAPY, pages 669-848

Note: Page numbers of issue and article titles are in **boldface** type.

Abortion, spontaneous, in diabetic pregnancies, 537-538

Academic career, in neonatal medicine, 1-8
basic science pathway in, 2-3
clinical, 6-7
fellowship programs for, 3-4
motivation for, 2
paths for, 2
post fellowship programs for, 4
research support and, 4-6
teaching in, 7
training programs for, 2

Academic function, perinatal asphyxia effects on, 490-491

Acetoacetate, excessive, in diabetic pregnancies, congenital anomalies and, 523

Acidemia, in perinatal asphyxia, 290-293, 330-332

Acidosis, umbilical blood sampling in, 70-71

Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection*.

Addiction, to cocaine. See *Cocaine use*.

Addiction Severity Index, 35

Adenosine deaminase deficiency, gene therapy in, 163-164

Adrenal gland, fetal, in labor initiation, 9-16

Adrenocorticotrophic hormone, fetal, in labor initiation, 9-14

Adult respiratory distress syndrome. See *Respiratory distress syndrome (adult)*.

AIDS. See *Human immunodeficiency virus infection*.

Airway stabilization, surfactant in, 761-762

Albumin excretion, in diabetic nephropathy, incipient, 562

Alcohol abuse, in women, 31-32
treatment of, 36-39

ALEC (artificial lung expanding compound), 818
in respiratory distress syndrome (neonatal), 738-739

Alkalosis, metabolic, induced, in pulmonary hypertension, 136

Allopurinol, in cerebral hypoxia-ischemia, 413-414

Alpha adrenergic blocking agents, in hypertension, in diabetic nephropathy, 567

Alpha tocopherol, in cerebral hypoxia-ischemia, 418

Alpha-fetoprotein, in congenital anomaly diagnosis, 541-542, 544

Alveofact. See *SF-R1 1*.

Alveolar capillary dysplasia, 131

Alveolar-arterial oxygen gradient, in pulmonary hypertension, 133

Amniocentesis, in isoimmune hemolytic disease, 62

Amniotic fluid, in diabetic pregnancies, prostaglandins in, 639-640
volume of, 553
meconium in, as asphyxia indicator, 328-329

surfactant extract from, 713, 817
in respiratory distress syndrome (neonatal), 725-726
in established disease, 719

Amniotic fluid (*Continued*)
prophylactic, 716-718

Androstenedione, fetal, labor initiation and, 15-16

Anemia, in diabetic nephropathy, 563, 567
isoimmune hemolytic, erythropoietin therapy in, 179-180
umbilical blood sampling in, 61-65

of prematurity, 169-191
erythropoietin therapy in, 183-186
normal erythropoiesis and, 170-173
pathophysiology of, 174-176

Anencephaly, pregnancy length in, 14-16

Animal models, of adult respiratory distress syndrome, 769-773
of gene transfer, 160-165
of hypoxic-ischemic encephalopathy, 359-363

of labor, primates as, 14-17
sheep as, 9-14

of perinatal asphyxia, magnetic resonance spectroscopy studies of, 359-363
visual evoked potentials and, 454

of respiratory distress syndrome (neonatal), surfactant therapy in, 714-715
of surfactant metabolism, 690-692

Antiarhythmic drugs, in fetal tachyarrhythmias, 73

Antibacterial activity, of surfactant, 763, 765

Antibiotics, for intrauterine device insertion, 658

Antibodies, to lung, surfactant depletion from, 771-772

Antitendotoxin antibody, in streptococcal infections, 219-220

Anti-inflammatory activity, of surfactant, 765

Antioxidants, in cerebral hypoxia-ischemia, 417-419

Aortic valve, atresia of, in hypoplastic left-heart syndrome, 145

Apgar scores, in perinatal asphyxia, 294-296, 330

Apnea, recurrent, in surfactant therapy, 750

Arachidonic acid deficiency, congenital anomalies in, 522, 528

ARDS. See *Respiratory distress syndrome (adult)*.

Arm ergometry, in gestational diabetes, 627-628

Artificial lung expanding compound, 818
in respiratory distress syndrome (neonatal), 738-739

Asphyxia, perinatal. See *Perinatal asphyxia*.

Aspiration pneumonia, surfactants in, 775

Asthma, surfactants in, 779-780

Atrial flutter/fibrillation, umbilical blood sampling in, 72-73

Atrioventricular dissociation, congenital, 93-94

Auditory brain stem evoked potentials, in perinatal asphyxia, 469-470

Autoimmune disease, maternal, congenital heart block in, 93

Azathioprine, in heart transplantation, 151-152

Azidothymidine, in HIV infection, in pregnancy, 48-53

Bacterial pneumonia, surfactants in, 775-776

Balance, Wilhelmy-Langmuir, in surfactant surface tension measurement, 669-671

Base excess, in perinatal asphyxia, 291

Beractant (Survanta), development of, 713
in respiratory distress syndrome (neonatal), in animal studies, 818-821
in established disease, 720-721
prophylactic, 716-718

Bergman's minimal model estimation of insulin sensitivity, in gestational diabetes, 587-588
in pregnancy, 585-586

Bernard-Soulier syndrome, umbilical blood sampling in, 67

Beta cell dysfunction, in gestational diabetes, 603-604

Birth asphyxia. See *Perinatal asphyxia*.

Blackfan-Diamond syndrome, erythropoietin, 174

Bleomycin, pulmonary fibrosis induced by, surfactant therapy in, 779

Blood flow, cerebral, near infrared spectroscopic quantification of, 371-372

Blood sampling, umbilical. See *Umbilical blood sampling*.

Blood volume, cerebral, near infrared spectroscopic quantification of, 372

Bovine spongiform encephalitis, transmission of, in surfactant therapy, 729-730

Bradycardia, fetal, delivery route for, 93

Brain, blood flow in, near infrared spectroscopic quantification of, 371-372

blood volume of, near infrared spectroscopic quantification of, 372

computed tomography of, in asphyxia, 380-381

edema of, after asphyxia, 316

glucose metabolism in, PET studies of, 396-399

hemorrhage of, in surfactant therapy, 730
in thrombocytopenic disorders, 65-67
SPECT in, 388-389

hypoxic injury of. See also *Hypoxic-ischemic encephalopathy*.
irreversible, 312
near infrared spectroscopy of, 369-378

infarction in, after asphyxia, 314-315
SPECT in, 388-389

normal maturation of, magnetic resonance imaging of, 348-351
magnetic resonance spectroscopy in, 355

nuclear magnetic resonance examination of. See *Nuclear magnetic resonance technology, in perinatal asphyxia*.
ultrasonography of, in asphyxia, 380

Brain scan, in asphyxia, 382-383

Breast milk. See *Milk, human*.

Breastfeeding, 225-243
infection transmission in, bacterial, 235-236
cytomegalovirus, 232-233
Epstein-Barr virus, 234-235
from mastitis, 236
from skin lesions, 236
hepatitis B, 233-234
herpes simplex virus, 234
HIV, evidence for, 230-232
in perinatal period, 229-230
worldwide perspective of, 228-229

human T lymphotropic virus type 1, 233
mechanisms for, 227-228
proving, 228
rubella, 234
toxoplasmosis, 236
trichinosis, 237
tuberculosis, 236
protective effects of, 225-227

Breathing, fetal, in diabetic pregnancy, 553

Bronchial smooth muscle, surfactant effects on, 765-766

Bronchitis, chronic, surfactants in, 781

Bronchopulmonary dysplasia, in surfactant therapy of RDS, 724, 726, 751-752

CAGE questionnaire, for substance abuse, 34

Calcium channel blockers, in cerebral hypoxia-ischemia, 420-421
in hypertension, in diabetic nephropathy, 567

Calf lung surfactant extract (Infrasurf), 818
development of, 713
in respiratory distress syndrome (neonatal), 725-726, 728
in animal studies, 818-821
prophylactic, 716-717

Captive bubble method, in surfactant surface tension measurement, 672-682

Cardiomyopathy, hypertrophic, in infant of diabetic mother, 637

Cardiovascular disorders, fetal/neonatal, in diabetic pregnancies, 519, 637
maternal, in oral contraceptive use, 652

Cardiovascular system, cocaine effects on, 249

Cardiovascular training, in gestational diabetes, 627-628

Catalase, in cerebral hypoxia-ischemia, 417-418

Central nervous system. See also *Brain*.
cocaine effects on, 249
congenital anomalies of, in diabetic pregnancies, 518-519

Cerebral blood flow, near infrared spectroscopic quantification of, 371-372

Cerebral blood volume, near infrared spectroscopic quantification of, 372

Cerebral palsy, perinatal asphyxia and, 288-289, 488
PET studies of, 401-407

Cervix, dilatation of, biologic factors regulating, 21

Cesarean section, in congenital anomalies.
See *Delivery route, in congenital anomalies*.

indications for, in diabetic pregnancy, 558

Child abuse, in cocaine use, 256-257

Chlorpropamide, in gestational diabetes, 606-607

Cholesterol levels, oral contraceptive effects on, 651-652

Choreoathetosis, PET studies of, 404, 406

Chromophores, in brain tissue, near infrared spectroscopy of, 370

Ciliary activity, in lung, surfactant effects on, 763

CLSE. See *Calf lung surfactant extract*.

Cocaine use, in pregnancy, 29-45, 245-262
administration routes for, 30
as chronic illness, 29-30
assessment of, 32-36
continued in postnatal period, 254-257
drug combinations with, 257
epidemiology of, 29
incidence of, 245-246
indicators of, 33-34
mental health issues in, 31, 41, 255-256
neonatal effects of, birth outcomes and, 250
caregiving influences and, 254-257
long-term, 253-254

Cocaine use (*Continued*)
 neurobehavioral, 250–254
 sensory motor developmental, 252–253
 teratogenic, 248–250
 obstetric complications from, 246–247
 pharmacology of, 246–247
 professional attitudes toward, 32–33
 rehabilitation services for, 38–39
 screening for, 32–36, 247–248
 self-help groups for, 39
 sexual victimization and, 40
 societal stigma for, 32
 sociodemographic factors in, 31–32
 toxicology of, 35–36
 treatment of, 36–41

Cognitive function, perinatal asphyxia effects on, 490

Colfosceril palmitate. See *CPHT (synthetic surfactant)*.

Colostrum, immunologic substances in, 227

Compassionate care, in hypoplastic left-heart syndrome, 152

Computed tomography, in perinatal asphyxia, 380–381

Congenital anomalies, antenatal therapy of, 81–83

cocaine use and, 248–249

delivery route in. See under *Delivery route*.

in conjoined twins, 97–99

in diabetic pregnancies, 517–532, 533–547, 635–636

clinical manifestations of, 518–520

diagnosis of, 541–544

epidemiology of, 517–518

etiology of, 520

free oxygen radicals in, 526

genetic susceptibility and, 527

incidence of, 533–534

maternal vasculopathy and, 519–520

metabolic fuel alterations in, 533–537

common pathway for, 528

hyperglycemia, 520–523

hyperketonemia, 523–524

hypoglycemia, 525

prenatal testing for, 541–544

prevention of, 528–530, 539–541

somatomedin inhibitors in, 526–527

spontaneous abortion in, 537–538

zinc deficiency and, 527

of heart, erythropoietin therapy in, 179

Contraception, for diabetic woman, 649–661

- intruterine device, 656–658
- oral, 650–655
- progestins, 655–656

Contraction stress test, in diabetic pregnancy, 551–552

Corticosteroids, in heart transplantation, 151–152

Corticotropin-releasing hormone, in labor initiation, 10, 12

Cortisol, fetal, in labor initiation, 9–14

- inhibition of, in lung maturation, 638
- in insulin resistance, 622

CPHT (Exosurf, synthetic surfactant),
 composition of, 697–698, 701
 in respiratory distress syndrome (neonatal), 818

- adverse events from, 749–750
- animal studies of, 820–821
- antenatal steroid prophylaxis and, 756
- controlled trials of, 739–741
- dosage of, 754
- in Open Study of Infants at high risk of/with Respiratory Insufficiency, 748–749
- in treatment investigational new drug program, 748

in very low birth weight infants, 756

long-term results of, 757

physiologic issues in, 752–753

prophylactic, 741–743

- vs. rescue approach, 754, 756
- rescue trials with, 744–748, 754, 756
- safety considerations with, 756–757
- unmet expectation with, 750–752
- vs. mammalian surfactants, 756
- metabolism of, 701–705
- surface tension of, 679–682

C1q, surfactant protein A homology with, 793

Crack cocaine. See *Cocaine use*.

Crying, abnormalities in, from cocaine exposure, 252

Curosurf, development of, 713

- in respiratory distress syndrome (neonatal), 725, 729
- prophylactic, 718

Cyclosporine, in heart transplantation, 151–152

Cystic fibrosis, surfactant therapy in, 777–779

Cystic hygroma, delivery route for, 89–91

Cytomegalovirus infection, transmission of, in breastfeeding, 232–233

umbilical blood sampling in, 68–69

Deafness, in perinatal asphyxia, 488–489

Death, in surfactant therapy of RDS, 724–726

- intruterine, in maternal diabetes, 549–551, 564–565

Deferoxamine, in cerebral hypoxia-ischemia, 414–415

Dehydroepiandrosterone, fetal, labor initiation and, 15-16

Delivery, in diabetic pregnancy, 557-558

lung maturity assessment before, 639-640

Delivery route, disease transmission and, HIV infection, 229-230

in congenital anomalies, 81-106

- conjoined twins, 97-99
- cystic hygroma, 89-91
- heart block, 92-94
- hydrocephalus, 87-89
- meningomyelocele, 83-87
- monoamniotic twins, 97-99
- sacrococcygeal teratoma, 91-92
- ventral wall defects, 94-97

Depo-medroxyprogesterone acetate, for diabetic woman, 656

Detergent aerosol, in surfactant disruption, 770

Dexamethasone, fetal administration of, labor initiation and, 14, 16

Diabetes, gestational. See *Gestational diabetes*.

Diabetes mellitus, classification of, 514

contraception in, 649-661

- insulin-dependent, 652-653
- intrauterine device, 656-658
- non-insulin dependent, 655
- oral, 650-655
- progestins, 655-656

control of, in nephropathy, 566-567

in pregnancy, 539-540

- congenital anomaly rate and, 528-529
- in retinopathy, 579

in offsprings of diabetic mothers, 644

in pregnancy, congenital anomalies caused by. See *Congenital anomalies in diabetic pregnancies*.

control of, 539-540

- congenital anomaly rate and, 528-529

fetal growth evaluation in, 542-543

fetal surveillance in, 549-560

- contraction stress test in, 551-552
- delivery timing and route in, 557-558

Doppler studies in, 554-555

fetal biophysical profile in, 552-553

maternal assessment in, 553-554

nonstress test in, 552

programs for, 555-556

historical review of, 507-515

infant morbidity in. See *Infants of diabetic mothers*.

intrauterine death in, 549-551, 564-565

nephropathy in, 561-570

outcome of, 507-508, 512-515

preconception care in, 539-540

retinopathy in, 571-581

infection in, from intrauterine device, 657-658

nephropathy in. See *Diabetic nephropathy*.

preeclampsia in, 562-563

- intruterine death and, 550
- retinopathy in. See *Diabetic retinopathy*.

Diabetic embryopathy. See *Congenital anomalies in diabetic pregnancies*.

Diabetic nephropathy, in pregnancy, 561-570

- clinical features of, 561
- incipient, 562-563
- long-term effects of, 567-569
- overt, 563-564
- perinatal outcome in, 564-566
- treatment of, 566-567

Diabetic retinopathy, 571-581

- classification of, 572-573
- in pregnancy, 571-572, 577-580
- incidence of, 571-572
- nonproliferative, 572
- pathophysiology of, 573-577
- proliferative, 572-573
- treatment of, 572-573, 579-580

Diet, in diabetic nephropathy, 566-567

- in gestational diabetes, 605-606, 629-631

Dimethylthiourea, in cerebral hypoxia-ischemia, 418

Dipalmitoyl phosphatidylcholine, in surfactants, natural, 737-738, 815

- synthetic, metabolism of, 699-704
- synthetic, in respiratory distress syndrome (neonatal), 738

Dipalmitoyl phosphatidylcholine-phosphatidylglycerol mixtures, in respiratory distress syndrome (neonatal), 738-739

Diplegia, spastic, PET studies of, 402-403

Discriminant function analysis, in risk scoring for preterm birth, 109

Dopamine, in pulmonary hypertension, 136

Doppler studies, in fetal surveillance, in diabetic pregnancy, 554-555

Down syndrome, incidence of, in diabetic pregnancies, 542

Drug abuse, cocaine in. See *Cocaine use*.

Drug Abuse Screening Test, 34-35

Ductus arteriosus, patency of, in hypoplastic left-heart syndrome, 147-148

in surfactant therapy, 723, 727, 750

Echocardiography, in pulmonary hypertension, 132

Edema, brain, after asphyxia, 316

Edema (Continued)
 pulmonary, surfactant effects on, 762–763

Embryopathy, diabetic. See *Congenital anomalies, in diabetic pregnancies*.

Encephalitis, transmission of, in surfactant therapy, 729–730

Encephalocele, delivery route for, 84

Encephalopathy, hypoxic-ischemic. See *Hypoxic-ischemic encephalopathy*.

Endotoxin, antibody to, in streptococcal infections, 219–220

Enhorning pulsating-bubble surfactometer, in surfactant surface tension measurement, 671–672

Enteral feeding, of low birth weight infant, advancement of, 197–198
 hypocaloric, 198
 initiation of, 197–198

Epstein-Barr virus, transmission of, in breastfeeding, 234–235

Ergometer training, in gestational diabetes, 627–628

Erythropoiesis, in fetus, 170–172

Erythropoietin, adverse effects of, 177
 in anemia of prematurity, 169–191
 biology of, 172–173
 levels of, 174–176
 normal erythropoiesis and, 170–173
 treatment with, 183–186

in congenital heart disease, 179

in end-stage kidney disease, 176–178

in isoimmune hemolytic anemia, 179

Estrogens, anti-insulin properties of, 622

in oral contraceptives, for diabetic woman, 650–651

placental, labor initiation and, 13–15, 18–20

Euglycemic clamp technique, in insulin sensitivity assessment, in gestational diabetes, 588
 in pregnancy, 585–586

Evoked potentials, in asphyxia, auditory brain stem, 469–470
 somatosensory, 458–459, 463–482
 visual, 451–461, 470–471

Exercise, in gestational diabetes, 606, 624–629

Exosurf. See *CPHT (synthetic surfactant)*.

Extracorporeal membrane oxygenation, in pulmonary hypertension, 137–139

SPECT in, 388–389

Failure to thrive, maternal cocaine use and, 256–257

Fetal biophysical profile, in diabetic pregnancy, 552–553

Fetal monitoring, electronic, as predictor of asphyxia, 293–294

Fetus, congenital anomalies of, antenatal therapy of, 81–83

erythropoiesis in, 170–172

growth of, in diabetic pregnancy, 565–566
 evaluation of, 542–543
 in gestational diabetes, 611–613
 in large for gestational age infants, 636–637
 in small for gestational age infants, 637–638

hypothalamic-hypophyseal-adrenal axis of, in labor initiation, 9–14

of diabetic mother, breathing movements of, 553

growth of, 542–543, 565–566

intrauterine death of, 549–551, 564–565

malformations in. See *Congenital anomalies*.

movement of, 553–554

surveillance of, 549–560
 contraction stress test in, 551–552
 Doppler studies in, 554–555
 fetal biophysical profile in, 552–553
 in gestational diabetes, 556–557
 lung maturity evaluation in, 558
 maternal assessment in, 553–554
 nonstress test in, 552
 programs for, 555–556
 tone of, 553

small for gestational age, umbilical blood sampling in, 70–71

thrombocytopenic disorders in, umbilical blood sampling in, 65–67

transition to neonatal circulation in, pulmonary hypertension and, 128–131

umbilical blood sampling in. See *Umbilical blood sampling*.

Fibrosis, pulmonary, surfactants in, 779

Fluid dispersal, in lung, surfactant effects on, 763

Flunarizine, in cerebral hypoxia-ischemia, 421

Folic acid supplementation, in diabetic pregnancies, 540–541

Fontan procedure, in hypoplastic left-heart syndrome, 149–150

Free radicals, in diabetic embryopathy, 526, 528

inhibitors/scavengers of, in hypoxic-ischemic encephalopathy, 412–419

release of, after perinatal asphyxia, 313

Gastrointestinal system, congenital anomalies of, in diabetic pregnancies, 519

Gastroschisis, delivery route for, 94–97
 Gaucher's disease, gene therapy in, 164–165
 Gavage feeding, of low birth weight infants, 203–204
 Gene transfer, into hematopoietic cells, 155–168
 animal models for, 160–165
 indications for, 163–165
 modalities for, 156–160
 Moloney murine leukemia virus in, 156
 packaging cell lines in, 157–159
 safety issues in, 162–163
 target cells for, 159–160
 vector construction in, 156–157
 Genetic factors, in diabetic embryopathy, 527
 Genetically engineered surfactants, 791–811
 in respiratory distress syndrome, animal studies of, 804–808
 surfactant protein characteristics and, 792–804
 Gestational age, perinatal asphyxia and, 309–310
 Gestational diabetes, 603–617, 619–634
 complications of, 611–613
 contraception in, 654–655
 diagnosis of, 584, 593–602
 glucose tolerance test in, 597–600
 screening tests for, 593–597
 fetal surveillance in, 556–557
 glucagon levels in, 587
 glucose levels in, 587
 in obese patients, 605–606
 incidence of, 619
 insulin levels in, 587
 insulin release in, 588–589
 insulin sensitivity in, 587–588
 ketonuria in, 629–630
 lipid levels in, 587
 management of, 605–613
 diet in, 605–606, 629–631
 exercise in, 606, 624–629
 insulin in, 607–610, 613
 optimum glucose levels in, 610–613
 oral hypoglycemic agents in, 606–608, 631
 metabolic changes in, 583–591
 offspring diabetes mellitus development and, 644
 pathogenesis of, 603–605
 pathophysiology of, 620–623
 risk factors for, 594–595, 619–620
 screening for, 594–597
 reasons for, 593–594
 vs. diabetes mellitus, 583
 Glenn anastomosis, in hypoplastic left-heart syndrome, 149–150
 Glibenclamide, in gestational diabetes, 631
 Glomerular filtration rate, in diabetic nephropathy, 563
 Glucagon levels, in gestational diabetes, 587
 in pregnancy, 585
 Glucocerebrosidase deficiency, gene therapy in, 164–165
 Glucose, absorption of, diet effects on, 605
 cerebral, PET studies of, 396–399
 role in hypoxic-ischemic encephalopathy, 421–423
 levels of. See also *Hyperglycemia; Hypoglycemia*.
 determination of, strip tests in, 640
 exercise effects on, 624
 in diabetic pregnancies, congenital anomalies and, 520–523, 525–526, 528–529
 in gestational diabetes, 587
 in normal pregnancy, 584–585
 metabolism of, 574–575
 oral contraceptive effects on, 651
 Glucose tolerance test, in gestational diabetes, for diagnosis, 596–600
 for screening, 595–596
 Glutamate toxicity, in cerebral hypoxia-ischemia, 419–420
 Glyburide, in gestational diabetes, 606–607
 Glycohemoglobin, in diabetic pregnancies, congenital anomaly rate and, 535–537
 spontaneous abortion rate and, 537–538
 vs. alpha-fetoprotein levels, 542
 Glypizide, in gestational diabetes, 607
 Graves' disease, maternal, umbilical blood sampling in, 72
 Growth, fetal, in diabetic pregnancy, 565–566
 evaluation of, 542–543
 in gestational diabetes, 611–613
 in large for gestational age infants, 636–637
 in small for gestational age infants, 637–638
 retardation of, susceptibility to perinatal asphyxia in, 310–311
 perinatal asphyxia effects on, 489

 Handicapped infants, very low birth weight, prevalence of, 263–277
 Head circumference, cocaine use and, 250
 Heart, congenital disease of, erythropoietin therapy in, 179
 hypoplastic. See *Hypoplastic left-heart syndrome*.

Heart (*Continued*)
 transplantation of, in hypoplastic left-heart syndrome, 150-151

Heart block, congenital, delivery route for, 92-94

Heart rate, fetal, as asphyxia indicator, 329-330

HEAT questionnaire, for substance abuse, 34

Hematopoietic cells, gene transfer into. See under *Gene transfer*.

Hemiplegia, spastic, PET studies of, 403-404

Hemoglobin, vs. erythropoietin, 174

Hemoglobin A1C, in diabetic pregnancies, congenital anomaly rate and, 535-537

spontaneous abortion rate and, 537-538

vs. alpha-fetoprotein levels, 542

Hemolysis, isoimmune, erythropoietin therapy in, 179-180

umbilical blood sampling in, 61-65

Hemorrhage, intracranial, in surfactant therapy, 730

in thrombocytopenic disorders, 65-67

intraventricular, after asphyxia, 317

in surfactant therapy of RDS, 723-724

pulmonary, in surfactant therapy, 730, 749-750

Hepatitis B, transmission of, 729

in breastfeeding, 233-234

Herpes simplex virus, transmission of, in breastfeeding, 234

Hexadecanol, in synthetic surfactant. See also *CPHT (synthetic surfactant)*. metabolism of, 702

HIV infection. See *Human immunodeficiency virus infection*.

Hormones, in gestational diabetes, 621-622

Human immunodeficiency virus infection, cocaine use and, 246-247

in pregnancy, 49-60

anti-*Pneumocystis* therapy in, 48, 51, 53-54

antiviral drugs in, 48-53

immunotherapy in, 54-56

pneumonia with, surfactants in, 776

screening for, in human milk banking, 202

transmission of, in breastfeeding, evidence for, 230-232

worldwide perspective of, 228-229

in delivery, 229-230

in perinatal period, 229-232

vertical, 229-230

azidothymidine effects on, 48-49

immunotherapy effects on, 54-56

umbilical blood sampling in, 70

Human somatomammotropin, metabolic effects of, 623

Human T lymphotropic virus type 1, transmission of, in breastfeeding, 233

Hydrocephalus, antenatal treatment of, 89

delivery route for, 87-89

Hydrogen peroxide formation, prevention of, in cerebral hypoxia-ischemia, 413-414

β -Hydroxybutyrate levels, in diabetic pregnancies, congenital anomalies and, 523

Hyperbilirubinemia, asphyxia-related neurotoxicity and, 362-363

Hyperglycemia, in diabetic pregnancies, congenital anomalies and, 520-523, 528-529

intruterine death and, 550

protective role of, in hypoxic-ischemic encephalopathy, 422-423

retinopathy in, 573

Hyperimmune immunoglobulin therapy, in infections, 218-221

Hyperinsulinemia, fetal, intruterine death and, 550-551

lung maturation and, 638-639

macrosomia and, 636-637

neonatal hypoglycemia and, 641

Hyperketonemia, in diabetic pregnancies, congenital anomalies and, 523-524

Hypertension, in diabetic nephropathy, 563-564

control of, 567

persistent pulmonary. See *Persistent pulmonary hypertension*.

Hyperthyroidism, umbilical blood sampling in, 71-72

Hyperventilation, therapeutic, in pulmonary hypertension, 134-135, 139

Hyperventilation/hyperoxia test, in pulmonary hypertension, 132

Hypocalcemia, in infant of diabetic mother, 642-643

Hypoglycemia, in diabetic pregnancies, congenital anomalies and, 525-526

in infant of diabetic mother, 640-642

Hypoglycemic agents, oral, in gestational diabetes, 606-608, 631

Hypomagnesemia, in infant of diabetic mother, 643

Hypoplastic left-heart syndrome, 145-154

anatomy of, 145-146

anomalies associated with, 146

cardiac transplantation in, 150-152

compassionate care in, 152

genetic predisposition to, 146-147

Norwood operation in, 149-150

pathophysiology of, 147-148

preoperative management of, 148-149

prevalence of, 146

Hypothalamic-hypophyseal-adrenal axis, fetal, in labor initiation, 9-16

Hypothermia, in hypoxic-ischemic encephalopathy, 423-425

Hypothyroidism, umbilical blood sampling in, 71-72

Hypoxemia, in pulmonary hypertension, 131-133

repetitive, pathophysiology of, 310

Hypoxia, fetal, in maternal diabetes, 550

respiratory distress syndrome treatment response and, 727

umbilical blood sampling in, 70-71

Hypoxic-ischemic encephalopathy, 296

academic function in, 490-491

animal models of, 359-363

categories of, 484-488

cerebral palsy and, 488

cognitive ability effects of, 490

computed tomography in, 380-381

damage mechanisms after, 311-318

deafness in, 488-489

factors influencing outcome in, 309-311

growth effects of, 489

magnetic resonance imaging in, 351-352

magnetic resonance spectroscopy in, 355-356

near infrared spectroscopy in, 369-378

neuropsychologic effects of, 491-495

PET studies of, 399, 401

radionuclide brain scan in, 382-383

sonography in, 380

SPECT in, 386-392

therapy for, 411-432

- channel blockers in, 420-421
- excitatory amino acid antagonists in, 419-420
- free radical inhibitors/scavengers in, 412-419
- hypothermia in, 423-425
- primary preventive, 413-416
- secondary interventional, 417-419
- substrate availability considerations in, 421-433

Immune response, to surfactant therapy, 730

Immunoglobulin(s), as formula additives, 203

- in human milk, 225-227
- intravenous, in infections, 211-223
 - antiendotoxin antibody in, 219-220
 - as treatment, 212-215
 - hyperimmune type, 218-221
 - prophylactic, 215-218
 - streptococcal, 218-219

Immunologic substances, in human milk, 225-227

Immunosuppressive therapy, in heart transplantation, 151-152

Immunotherapy, in HIV infection, in pregnancy, 54-56

- in thrombocytopenic disorders, 67

Infants of diabetic mothers, 635-646

- complications in, 643-644
- congenital anomalies in. See *Congenital anomalies*.

diabetes mellitus development in, 644

growth disorders in, large for gestational age, 636-637

- small for gestational age, 637-638
- hypocalcemia in, 642-643
- hypoglycemia in, 640-642
- hypomagnesemia in, 643
- intellectual performance in, 643-644
- pulmonary development in, 638-640

Infarction, brain, after asphyxia, 314-315

Infections, congenital, umbilical blood sampling in, 67-70

- from intrauterine device, 657-658
- immunoglobulin therapy in, 211-223
 - antiendotoxin antibody in, 219-220
 - as treatment, 212-215
 - hyperimmune type, 218-221
 - prophylactic, 215-218
 - streptococcal, 218-219
- transmission of, in breastfeeding. See under *Breastfeeding*.
- in surfactant therapy, 729-730

Inflammation, surfactant reduction of, 765

Influenza, pneumonia in, surfactants in, 775

Infrasurf. See *Calf lung surfactant extract*.

Insulin, action of, 574

- early clinical trials of, 508-512
- estrogen antagonism of, 622
- in gestational diabetes, 607-610, 613
- levels of, in gestational diabetes, 587
 - in pregnancy, 584-585
- pulmonary surfactant synthesis and, 638-639
- release of, in gestational diabetes, 588-589
 - in pregnancy, 586
- resistance to, in gestational diabetes, 604-605, 620
- sensitivity to, in gestational diabetes, 587-588
 - in pregnancy, 585-586
- teratogenic testing of, 527-528

Intracranial hemorrhage, in surfactant therapy, 730

- in thrombocytopenic disorders, 65-67

Intrauterine death, in diabetic nephropathy, 564-565

Intrauterine death (*Continued*)
 in maternal diabetes, 549-551
 Intrauterine device, for diabetic woman, 656-658
 Intravenous glucose tolerance test, in gestational diabetes, 597, 600
 Intraventricular hemorrhage, after asphyxia, 317
 in surfactant therapy of RDS, 723-724
 Iron elimination, in cerebral hypoxia-ischemia, 414-415
 Isoimmunization, red blood cell, erythropoietin therapy in, 179-180
 umbilical blood sampling in, 61-65

Kell antibodies, umbilical blood sampling for, 62-63
 Ketoacidosis, in pregnancy, intrauterine death and, 550
 treatment of, 512
 Ketones, in diabetic pregnancies, congenital anomalies and, 523-524
 in gestational diabetes, 629-630
 Kidney, diabetic involvement of. See *Diabetic nephropathy*.
 erythropoietin production in, 172-173
 failure of, erythropoietin therapy in, 176-178

Labor, biologic basis of, 9-27
 cervical dilatation in, 21
 contracture-to-contraction switch in, 20-21
 fetal hypothalamic-hypophyseal-adrenal axis in, 9-13
 in preterm labor, 21-22
 in primates, 14-17
 in sheep, 9-14
 myometrial activity in, 17-22
 placental events in, 13-14
 prostaglandins in, 13-14, 21
 response to oxytocin and, 20
 stressors in, 22
 cerebral oxygenation assessment during, 375-376
 Large for gestational age infants, maternal diabetes and, 636-637
 La/SSB autoantibodies, congenital heart block and, 93
 Lavage, in surfactant depletion, 771
 Lazeroids, in cerebral hypoxia-ischemia, 418
 Lecithin/sphingomyelin ratio, in diabetic pregnancy, 558, 639-640
 surfactant therapy effects on, 692-693

Left heart hypoplasia. See *Hypoplastic left-heart syndrome*.
 Levonorgestrel, in oral contraceptives, 651
 Lipid levels, in gestational diabetes, 587
 in pregnancy, 584
 oral contraceptive effects on, 651-652
 Lipid peroxidation, diabetic embryopathy and, 526, 528
 Lipid-extract surfactant, surface tension of, 675, 677
 Liver, erythropoietin production in, 172-173
 Logistic regression, in risk scoring for preterm birth, 110
 Low birth weight infants, handicapped, prevalence of, 263-277
 head circumference of, 250
 nutrition in. See under *Nutrition*.
 Lung. See also *Pulmonary*.
 antibodies to, surfactant depletion from, 771-772
 microstructure of, surfactant surface tension effects on, 669
 transplantation, surfactants in, 776-777
 Lung maturity, fetal, in diabetic pregnancy, 638-640
 evaluation of, 558
 Lymphocytes, in human milk, 227
 Lysophospholipids, antibacterial activity of, 765

Macrophages, in human milk, 227
 Macrosomia, in diabetes mellitus, 636-637
 in gestational diabetes, pathophysiology of, 611-612
 prevention of, 613
 Magnetic resonance imaging, 346-353
 fundamentals of, 346-348
 in asphyxia, 351-352
 timing of, vs. neurodevelopmental outcome, 352-353
 normal brain maturation and, 348-351
 Malformations, congenital. See *Congenital anomalies*.
 Mannose-binding proteins, surfactant protein A homology with, 793-794
 Mastitis, breastfeeding with, 236
 May-Hegglin anomaly, umbilical blood sampling in, 67
 Mechanical ventilation, in pulmonary hypertension, 134-135
 surfactant therapy with, 730, 750-752
 Meconium aspiration syndrome, surfactants in, 777
 Meconium staining, in asphyxia, 328-329

Median nerve somatosensory evoked potentials, in perinatal asphyxia, 464-468

Meningitis, in myelomeningocele, 86

Meningomyelocele, delivery route for, 83-87

Mental health issues, in cocaine use, 31, 41, 255-258

Mestranol, in oral contraceptives, for diabetic woman, 650

Metabolic alkalosis, induced, in pulmonary hypertension, 136

Metabolic changes, in gestational diabetes, 583-591

- in pregnancy, 584-586

Metabolic fuel changes, diabetic embryopathy and. *See Congenital anomalies, in diabetic pregnancies.*

Metabolic status, perinatal asphyxia and, 309

Metformin, in gestational diabetes, 631

2-Methylaminochromans, in cerebral hypoxia-ischemia, 418

N-Methyl-D-aspartate, in cerebral hypoxia-ischemia, 416

Michigan Alcoholism Screening Test, 34-35

Microalbuminuria, in diabetic nephropathy, 562

Microangiopathy, retinal, in diabetes mellitus, 575-577

Milk, human. *See also Breastfeeding.*

- bacteria in, 235-236
- banking of, 201-202
- contamination of, 227-228
- for low birth weight infant, 197-198, 200-202
- fortifiers for, 200-201
- immunologic substances in, 225-227

Mitral valve, atresia of, in hypoplastic left-heart syndrome, 145

MK-801, in cerebral hypoxia-ischemia, 420

Moloney murine leukemia virus, in gene transfer, 156

Monitoring, fetal, in diabetic pregnancy. *See Fetus, of diabetic mother, surveillance of.*

Monoclonal antibodies, in streptococcal infections, 219

Morbidity index, in perinatal asphyxia, 299-300

Motor activity, cocaine exposure effects on, 252-253

Mucous plugs, in surfactant therapy, 750

Mucus properties, surfactant effects on, 763

- in chronic bronchitis, 781
- in cystic fibrosis, 777-779

Multiple organ dysfunction, in perinatal asphyxia, 297-298

Multivariate risk scoring, for preterm birth, 108-110

Mycoplasma pneumoniae pneumonia, pneumonia in, 776

Myoinositol, deficiency of, in congenital anomalies, 522, 528-529

- fetal lung maturation and, 638

Myometrium, activity patterns of, 17-22

Nasogastric tube, in enteral feeding, 203

National Collaborative Perinatal Project, 436-437

Near infrared spectroscopy, in perinatal asphyxia, 369-378

- during labor, 375-376
- hemodynamic variable quantification in, 371-372
- limitations of, 372-373
- principles of, 369-371

Necrotizing enterocolitis, breast milk protection against, 227

- enteral feeding and, 196, 198

Neonatal medicine, academic career in. *See Academic career.*

Neovascularization, in diabetic retinopathy, 576-577

Nephrotic syndrome, in diabetic nephropathy, 563

Neural tube defects, delivery route for, 83-87

- prenatal diagnosis of, 83-84
- alpha-fetoprotein in, 541-542
- prevention of, with folic acid supplementation, 540-541

Neurobehavioral effects, of cocaine exposure, 250-254

Neurological disorders, after perinatal asphyxia, 296-297

- in pulmonary hypertension, 139

Neurologic examination, in perinatal asphyxia, 484-489

Neuropsychologic skills, perinatal asphyxia effects on, 491-495

Neurotransmitter antagonists, in cerebral hypoxia-ischemia, 419-420

Nimodipine, in cerebral hypoxia-ischemia, 421

Nitric oxide, in pulmonary hypertension, 137

Nitric oxide inhibition, in cerebral hypoxia-ischemia, 415-416

Nitroglycerin, in pulmonary hypertension, 137

NCCGDD Nitro-L arginine methyl ester, in cerebral hypoxia-ischemia, 416

N-Nitroso-N-methyl urea infusion, as ARDS model, 772-773

Nonnutritive sucking, for preterm infants, 204-205

Nonstress test, in diabetic pregnancy, 552

No-reflow phenomenon, in perinatal asphyxia, 312-313

Noroethindrone, in oral contraceptives, for diabetic woman, 651

Norplant, for diabetic woman, 656

Norwood operation, in hypoplastic left heart syndrome, 149-150

Nuclear magnetic resonance spectroscopy, 353-363

- fundamentals of, 353-354
- in asphyxia, 355-356, 359-363
- modifications of, 356-357
- normal brain maturation and, 355
- proton, 357-359, 361-362

Nuclear magnetic resonance technology, in perinatal asphyxia, 345-367

- imaging, 346-353
- spectroscopy, 353-363

Nutrition. See also *Breastfeeding*.

- in low birth weight infant, 193-209
- advancement of, 197-198
- feeding methods for, 203-204
- formulas for, 202-203
- goals of, 193-197
- human milk in, 197-198, 200-202
- initiation of, 197-198
- long-term effects of, 196-197
- milk banking in, 201-202
- nonnutritive sucking with, 204-205
- theoretical requirements in, 194

Obesity, gestational diabetes in, 605-606

Omphalocele, delivery route for, 94-97

Open Study of Infants at high risk of, or with, Respiratory Insufficiency, surfactants in, 748-749

Oral glucose tolerance test, in gestational diabetes, for diagnosis, 596-600

- for screening, 595-596

Oral hypoglycemic agents, in gestational diabetes, 606-608, 631

Orogastric tube, in enteral feeding, 203

Osteopetrosis, gene therapy in, 164

Oxygen, partial pressure of, in pulmonary hypertension, 132-133

Oxygen therapy, in small for gestational age fetus, 71

Oxygen toxicity model, of ARDS, 772

Oxygenation, evaluation of, in pulmonary hypertension, 132-133

Oxygenation index, in pulmonary hypertension, 133

Oxygen-free radical inhibitors/scavengers, in hypoxic-ischemic encephalopathy, 412-419

Oxypurinol, in cerebral hypoxia-ischemia, 414

Oxytocin, antagonists to, in preterm labor, 21-22

- secretion of, diurnal rhythm of, 20

Parenteral nutrition, for low birth weight infant, 197-198

Parenting, cocaine use effects on, 254-257

Parvovirus infection, umbilical blood sampling in, 69

Patent ductus arteriosus, in surfactant therapy, 750

- in surfactant therapy of RDS, 723
- respiratory distress syndrome treatment response and, 727

Pedersen's theory, of macrosomia, 611-612, 636-637

Pelvic inflammatory disease, from intrauterine device, 657-658

Pentamidine, in *Pneumocystis* prophylaxis, in pregnancy, 53-54

Peptides, synthetic, in surfactant compositions, 824-826

Percutaneous umbilical blood sampling. See *Umbilical blood sampling*.

Perinatal asphyxia, acidemia in, 290-293, 330-332

- adaptive responses to, 306-307
- animal models for, 359-363, 454
- Apgar scores in, 294-296, 330
- as syndrome, 332-335
- auditory brain stem evoked potentials in, 469-470
- base excess in, 291
- biochemical indices of, 289
- biologic risks for, 433-449
- confounding issues in, 434-436
- brain edema after, 316
- brain infarction after, 314-315
- brain scanning in, 382-383
- cerebral palsy and, 288-289, 488
- computed tomography in, 380-381
- definition of, 287-304
- depression phase after, 313-314
- differential diagnosis of, 338-339
- encephalopathy in. See *Hypoxic-ischemic encephalopathy*.
- environmental issues in, 436
- experimental, 337-338
- fetal heart rate and, 329-330
- fetal monitoring prediction of, 293-294
- free radical release in, 313
- gestational age and, 309-310

historical perspectives on, 288–289
 hyperbilirubinemia and, 362–363
 in growth retardation, 310–311
 in umbilical cord occlusion, 310
 indicators of, 327–344

- as single elements, 328–332
- elements together, 332–335
- later, 332

 long-term effects of, 483–500

- academic function, 490–491
- cognitive ability, 490
- growth, 489
- neonatal neurologic examination in, 484–489
- neuropsychologic skills, 491–495
- sexual maturation, 490

 meconium staining in, 328–329
 metabolic status in, 309
 morbidity index in, 299–300
 multiple organ dysfunction in, 297–298
 near infrared spectroscopy in, 369–378
 neurologic examination in, 484–489
 neurological sequelae of, 296–297
 no-reflow phenomenon in, 312–313
 nuclear magnetic resonance technology in, 345–367

- imaging, 346–353
- spectroscopy, 353–363

 pathophysiology of, 305–325

- adaptive responses in, 306–307
- factors influencing, 309–311
- primary causes in, 335–336
- secondary damage, 311–318, 335–336
- severe, 307–308

 placental pathology in, 336
 positron emission tomography in, 399, 401
 recovery profiles in, 314
 reperfusion after, 312–313
 repetitive hypoxemia and, 310
 respiratory distress syndrome treatment response and, 727

- secondary damage in, 311–318
- seizures after, 315–316
- severe, pathophysiology of, 307–308
- single photon emission computed tomography in, 379–394
- somatosensory potentials in, 458–459, 463–482
- sonography in, 380
- stroke after, 316–317
- visual evoked potentials in, 451–461, 470–472

 Peroxidation, lipid, diabetic embryopathy and, 526, 528
 Persistent pulmonary hypertension, 127–143

- alveolar capillary dysplasia in, 131
- diagnosis of, 131–133

 epidemiology of, 127–128
 excessive vascular muscularization in, 131
 maladaptive form of, 129–131
 neurodevelopmental outcome in, 138–139
 pathophysiology of, 128–131
 treatment of, 133–138
 vascular malalignment in, 131
 PET. See *Positron emission tomography*.
 Phase-modulated rotating frame imaging, as nuclear magnetic resonance spectroscopy modification, 357
 Phosphatidylcholine, in surfactants, 815

- metabolism of, 698–699
- synthesis of, 698

 Phosphatidylglycerol, in surfactants, natural, 700, 815

- synthetic, 738

 Phosphatidylinositol, in natural surfactants, 815
 Phospholipid(s), in surfactants, 815–816
 Pituitary gland, fetal, in labor initiation, 9–16
 Placenta, abnormalities of, in perinatal asphyxia, 336
 progesterone in, labor initiation and, 13–14
 Platelet transfusion, in thrombocytopenic disorders, 66–67
Pneumocystis carinii, chemotherapy for, in pregnancy, 48, 51, 53–54
 Pneumonia, surfactant therapy in, 774–776
 Pneumothorax, in surfactant therapy of RDS, 722–723, 726
 Polio virus antibodies, in human milk, 226
 Polyethylene glycol-catalase, in cerebral hypoxia-ischemia, 417–418
 Polyethylene glycol-superoxide dismutase, in cerebral hypoxia-ischemia, 417–418
 Polyl pathway, in diabetes mellitus, 575
 Positron emission tomography, 395–409

- dosimetry in, 396
- in cerebral palsy, 401–407
- in perinatal asphyxia, 399, 401
- normative data in, 396–399
- principles of, 395–396

 Prednisone, in heart transplantation, 151–152
 Preeclampsia, in diabetic nephropathy, 562–564

- intruterine death and, 550

 Pregnancy, anti-*Pneumocystis* therapy in, 48, 51, 53–54

- cocaine addiction in. See under *Cocaine use*

 diabetes in. See *Diabetes mellitus; Gestational diabetes*.
 exercise in, safety of, 624–626

Pregnancy (*Continued*)
 glucagon levels in, 585
 glucose levels in, 584-585
 HIV infection in, treatment of, 49-60
 immunotherapy in, in HIV infection, 54-56
 insulin sensitivity in, 585-586
 lipid levels in, 584
 umbilical blood sampling in. See *Umbilical blood sampling*.

Premature infants, low birth weight. See *Low birth weight infants*.

respiratory distress syndrome in. See *Respiratory distress syndrome (neonatal)*.

surfactant metabolism in, 687-690
 surfactant pool size in, 684-686

Prematurity, anemia of. See *Anemia, of prematurity*.

Preterm birth, of infants of diabetic mothers, with nephropathy, 566
 risk scoring for, 107-125
 definitions in, 119-120
 difficulties with, 118-122
 evaluation of, 110-111
 literature review of, 115-118
 methods for, 107-110
 population specificity of, 120-121
 predictive value of, 111
 preventive interventions and, 120
 reliability of, 111
 review of, 111-115
 risk factor identification in, 118-119
 sensitivity of, 110-111
 specificity of, 110-111
 statistical limitations of, 121-122

Preterm labor, biochemical factors in, 21-22

Progesterin, for diabetic woman, 657

Progesterone, glucose metabolism effects of, 622
 placental, labor initiation and, 13-14

Progestins, glucose metabolic effects of, 651
 in contraceptives, for diabetic woman, long-acting, 655-656
 oral, 650
 lipid levels affected by, 651-652

Prolactin, metabolic effects of, 622-623

Propylthiouracil, fetal hypothyroidism from, 72

Prostaglandins, in amniotic fluid, in diabetic pregnancies, 639-640
 in labor initiation, 13-14, 20-21
 in pulmonary hypertension, 137

Protein(s), dietary restriction of, in diabetic nephropathy, 566-567
 surfactant. See *Surfactant protein(s)*.

Proteinuria, in diabetic nephropathy, incipient, 562-563
 overt, 563-564

Proton magnetic resonance spectroscopy, 357-359, 361-362

Pulmonary disorders, surfactant in. See *Surfactant(s), in pulmonary disorders*.

Pulmonary edema, surfactant effects on, 762-763

Pulmonary fibrosis, surfactants in, 779

Pulmonary hemorrhage, in surfactant therapy, 730, 749-750

Pulmonary hypertension, persistent. See *Persistent pulmonary hypertension*.

Pulmonary maturity, fetal, in diabetic pregnancy, evaluation of, 558

Pulmonary pressure, measurement of, in pulmonary hypertension, 132

Pulmonary surfactant. See *Surfactant(s)*.

Pulsating-bubble surfactometer, in surfactant surface tension measurement, 671-672

Quadriplegia, spastic, PET studies of, 402

Radiation pneumonitis, surfactants in, 779

Radionuclide brain scan, in asphyxia, 382-383

Rat, surfactant from, surface tension of, 675

RDS. See *Respiratory distress syndrome*.

Recombinant surfactant proteins, 823-824

Red blood cell(s), gene transfer into, for disease treatment, 163-164

Red blood cell isoimmunization, erythropoietin therapy in, 179-180

umbilical blood sampling in, 61-65

Rehabilitation services, for cocaine addiction, 38-39

Reperfusion, after perinatal asphyxia, 312-313

Research, as academic career, 2-7

Respiratory distress syndrome (adult), 766-774
 pathogenesis of, 766-769
 surfactant abnormalities in, mechanisms of, 767-769
 replacement of, in animal models, 769-773

surfactant therapy in, 773-774
 third-generation, 826

Respiratory distress syndrome (neonatal), in infant of diabetic mother, 639
 prevention of, 715-718, 725-726

surfactants in. See *Surfactant(s), in respiratory distress syndrome (neonatal)*.

Retinopathy, diabetic. See *Diabetic retinopathy*.

Retroviruses, in gene transfer. *See Gene transfer.*
 Risk scoring, for preterm birth. *See under Preterm birth.*
 Ro/SSA autoantibodies, congenital heart block and, 93
 Rotavirus antibodies, in human milk, 226–227
 RU486, in labor initiation, 16–17
 Rubella, transmission of, in breastfeeding, 234

Sacrococcygeal teratoma, delivery route for, 91–92
 Screening, for cocaine use, in pregnancy, 32–36, 247–248
 for preterm birth. *See Preterm birth, risk scoring for.*
 Seizures, postasphyxic, 315–316
 Self-help groups, for substance abuse, 39
 Sendai virus, pneumonia in, surfactants in, 775
 Sensory motor activity, cocaine exposure effects on, 252–253
 Sepsis, neonatal, immunoglobulins in, as prophylaxis, 215–218
 as therapy, 212–215
 Sexual maturation, perinatal asphyxia effects on, 490
 Sexually transmitted diseases, in diabetic woman, 658
 SF-RI 1 (Alveofact surfactant), development of, 713
 in respiratory distress syndrome (neonatal), in established disease, 720
 prophylactic, 718
 Siamese twins, delivery route for, 97–99
 Single photon emission computed tomography, clinical applications of, 383–384
 in asphyxia, 386–392
 in cerebral infarction/hemorrhage, 388–389
 in extracorporeal membrane oxygenation, 388–389
 in neonates, 385
 in pediatric patients, 384–385
 normal appearance in, 386
 normative values for blood flow in, 385–386
 Small for gestational age fetus, umbilical blood sampling in, 70–71
 Small for gestational age infants, maternal diabetes and, 637–638
 Smoke inhalation, in surfactant deactivation, 770–771

Smooth muscle relaxation, surfactant in, 765–766
 Somatomedin inhibitors, diabetic embryopathy and, 526–527
 Somatosensory evoked potentials, in perinatal asphyxia, 463–482
 median nerve, 464–468
 posterior tibial nerve, 468–469
 vs. visual evoked potentials, 458–459, 470–472
 Sonography, in perinatal asphyxia, 380
 Sorbitol, in hyperglycemia, 522, 528, 575
 Spastic diplegia, PET studies of, 402–403
 Spastic hemiplegia, PET studies of, 403–404
 Spastic quadriplegia, PET studies of, 402
 SPECT. *See Single photon emission computed tomography.*
 Spectroscopy, in perinatal asphyxia, near infrared, 369–378
 nuclear magnetic resonance, 353–363
 Stem cells, hematopoietic, gene transfer into. *See under Gene transfer.*
 Stillbirth. *See Intrauterine death.*
 Streptococcal infections, immunoglobulin therapy in, 218–219
 Stress, maternal, preterm labor in, 22
 Strip tests, for glucose, 640
 Stroke, after asphyxia, 316–317
 Substance abuse, cocaine in. *See Cocaine use.*
 Sucking, nonnutritive, for preterm infants, 204–205
 Sudden infant death syndrome, cocaine use and, 250
 Superoxide dismutase, diabetic embryopathy and, 526
 in cerebral hypoxia-ischemia, 417–418
 Superoxide radical formation, prevention of, in cerebral hypoxia-ischemia, 413–414
 Supraventricular tachycardia, umbilical blood sampling in, 72–73
 Surface tension, of surfactant. *See under Surfactant(s).*
 Surfactant(s), antibacterial activity of, 763, 765
 anti-inflammatory activity of, 765
 biosynthesis of, 698–699
 insulin effects on, 638
 bovine, 818
 development of, 712–713
 in respiratory distress syndrome (neonatal), 725–726, 729
 in established disease, 720
 prophylactic, 716
 ciliary motility and, 763
 clearance of, 699–700
 deficiency of, in ARDS, 767
 designer, 813–829

Surfactant(s) (*Continued*)

- natural surfactants and, biophysical properties of, 814-815
- composition of, 815-816
- mammalian-based, 817-818
- recombinant, 823-824
- synthetic peptides, 824-826
- synthetic surfactants and, 818
- third-generation, 821-826
- vs. currently available surfactant preparations, 818-821
- extra-alveolar, mechanism of action, 761-762
- from amniotic fluid, 713, 817
- in respiratory distress syndrome (neonatal), 725-726
 - in established disease, 719-720
 - prophylactic, 716-718
- function of, vs. metabolism, 694
- genetically engineered, 791-811
 - in respiratory distress syndrome, animal studies of, 804-808
 - surfactant protein characteristics and, 792-804
- heterologous, definition of, 712
- homologous, definition of, 712
- in adult respiratory distress syndrome, 766-774, 826
 - in airway stabilization, 761-762
 - in asthma, 779-780
 - in chronic bronchitis, 781
 - in cystic fibrosis, 777-779
 - in edema reduction, 762-763
 - in fluid dispersal, 763
 - in lung transplantation, 776-777
 - in meconium aspiration, 777
 - in mucus property alteration, 763
 - in pneumonia, 774-776
 - in pulmonary disorders, 761-789. See also subhead: *in respiratory distress syndrome*.
 - adult respiratory distress syndrome, 766-774
 - asthma, 779-780
 - chronic bronchitis, 781
 - cystic fibrosis, 777-779
 - lung transplantation, 776-777
 - mechanism of action, 761-766
 - meconium aspiration, 777
 - pneumonia, 774-776
 - pulmonary fibrosis, 779
 - in pulmonary fibrosis, 779
 - in respiratory distress syndrome (adult), 766-774
 - third-generation surfactants in, 826
 - in respiratory distress syndrome (neonatal), 711-735
 - bronchopulmonary dysplasia in, 724
 - complications of, 729-731
- complications of, 729-731
- mortality in, 724-725
- patent ductus arteriosus in, 723
- pneumothorax incidence in, 722-723
- prophylactic, 715-718, 725-726
- phospholipids of, 815-816
- pool size of, measurement of, 684

dosage effects on, 728-729

factors affecting response, 727-729

genetically engineered, 804-808

in animal models, 714-715

in established disease, 719-721, 725-726

intraventricular hemorrhage in, 723-724

lack of response to, 727

long-term results of, 731

metabolism of, 690-693

mortality in, 724-725

patent ductus arteriosus in, 723

pneumothorax incidence in, 722-723

prophylactic, 715-718, 725-726

protein metabolism in, 693-694

surfactant quality effects on, 727-728

in smooth muscle relaxation, 765-766

inactivation of, in ARDS, 767-768

lamellar form of, 698

lipid-extract, surface tension of, 675, 677

lung-associated (not recoverable by washing), 689

mechanism of action of, 761-766

metabolism of, 683-696, 699-700

- in adult, 687
- in animal models, 690-692
- in preterm lung, 687-690
- in respiratory distress syndrome (neonatal), 692-693
- in treatment, 690-694

overview of, 686-687

surfactant function and, 694

surfactant pool size and, 684-686

surfactant proteins and, 693-694

synthetic, 697-710

natural, 711-735

- absorption of, 815
- biophysical properties of, 814-815
- chemical composition of, 712
- composition of, 737-738, 815-816
- development of, 712-714
- in respiratory distress syndrome (neonatal), bronchopulmonary dysplasia in, 724
- complications of, 729-731
- factors affecting response, 727-729
- in animal models, 714-715
- in established disease, 719-721, 725-726

intraventricular hemorrhage in, 723-724

long-term results of, 731

mortality in, 724-725

patent ductus arteriosus in, 723

pneumothorax incidence in, 722-723

prophylactic, 715-718, 725-726

surfactant metabolism and, 684-686
 porcine, 818
 development of, 713
 in respiratory distress syndrome (adult), 774
 in respiratory distress syndrome (neonatal), 725-726, 728
 in established disease, 720
 prophylactic, 718
 quality of, treatment response and, 727-728
 rat, surface tension of, 675
 secretion of, 698-699
 surface tension properties of, 669-682
 effects on lung microstructure, 669
 measurement of, 669-682
 captive bubble method, 672-682
 Enhörning pulsating-bubble surfactometer in, 671-672
 Wilhelmy-Langmuir balance in, 669-671
 synthetic, 818. See also specific product, e.g., CPHT.
 in respiratory distress syndrome (adult), 774
 in respiratory distress syndrome (neonatal), 737-760
 artificial lung expanding compound, 738-739
 CPHT, 739-757
 early trials of, 738
 in established disease, 744-748
 metabolism of, 701-705
 overview of, 700-701
 Surfactant protein(s), functions of, 700-701, 713-714
 in natural surfactant extracts, 713-714
 metabolism of, 693-694
 surface tension effects of, 675, 677
 synthesis of, 698
 types of, 792
 Surfactant protein A, antibacterial activity of, 765
 cellular origin of, 795-796
 characteristics of, 792-796
 chemical structure of, 792-793
 composition of, 816
 immunogenicity of, 730
 metabolism of, 689
 recombinant, 823-824
 surface tension effects of, 677
 Surfactant protein B, characteristics of, 796-801
 chemical structure of, 796-798
 composition of, 816
 gene of, 799-800
 mechanism of action of, 800-801
 metabolism of, 690

peptides related to, in surfactant compositions, 824-826
 recombinant, 823
 secretion of, 798-799
 Surfactant protein C, characteristics of, 796, 801-804
 composition of, 816
 gene of, 802-803
 genetically engineered, 804-807
 in respiratory distress syndrome (neonatal), 804-807
 structure of, 801-802
 Surfactant protein D, 792, 794, 808
 Surfactant-TA, development of, 712-713
 in respiratory distress syndrome (neonatal), clinical trials of, 715
 factors affecting response, 727-728
 in established disease, 719
 prophylactic, 718
 Surfacten. See *Surfactant-TA*.
 Surfactometer, Enhörning pulsating-bubble, in surfactant surface tension measurement, 671-672
 Survanta. See *Beractant*.
 Synthetic surfactants. See under *Surfactant(s)*.
 Syphilis, umbilical blood sampling in, 70
 Tachyarrhythmia, umbilical blood sampling in, 72-73
 Taurine supplementation, in formulas, 202-203
 Teratogenic effects, of cocaine, 248-250
 of hyperglycemia, 520-523, 528-529
 of hyperketonemia, 523-524
 of oral hypoglycemic agents, 631
 of vitamin A, 527
 of zinc deficiency, 527
 Teratoma, sacrococcygeal, delivery route for, 91-92
 Thyroid disease, umbilical blood sampling in, 71-72
 Tibial nerve (posterior) somatosensory evoked potentials, in perinatal asphyxia, 468-469
 Tirilazad mesylate, in cerebral hypoxia-ischemia, 418
 Tolazoline, in pulmonary hypertension, 137
 Tolbutamide, in gestational diabetes, 606-607
 Toxoplasmosis, transmission of, in breastfeeding, 236
 umbilical blood sampling in, 67-68
 Training, for academic career. See *Academic career*.
 Transfusion, fetal hemoglobin loss during, 175-176

Transfusion (*Continued*)
 intrauterine, in isoimmune hemolytic disease, 63-65
 platelet, in thrombocytopenic disorders, 66-67

Transplantation, heart, in hypoplastic left heart syndrome, 150-151
 lung, surfactants in, 776-777

Transpyloric feeding, of low birth weight infants, 204

Trichinosis, transmission of, in breastfeeding, 237

Trimethoprim-sulfamethoxazole, in *Pneumocystis* prophylaxis, in pregnancy, 53-54

Tuberculosis, transmission of, in breastfeeding, 236

Twins, delivery route for, conjoined, 97-99
 monoamniotic, 97-99

Tylozapol. See also CPHT (*Exosurf, synthetic surfactant*).
 in synthetic surfactant, metabolism of, 704-705

U-74006F (tirilazad mesylate), in cerebral hypoxia-ischemia, 418

U-78517F (2-methylaminochromans), in cerebral hypoxia-ischemia, 418

Ultrasonography, in diabetic pregnancies, 542-544, 554-555
 in perinatal asphyxia, 380

Umbilical blood sampling, 61-80
 in Bernard-Soulier syndrome, 67
 in congenital infections, 67-70
 in cytomegalovirus infections, 68-69
 in HIV infection, 70
 in parvovirus infections, 69
 in red blood cell isoimmunization, 61-65
 in small for gestational age fetus, 70-71
 in syphilis, 70
 in tachyarrhythmias, 72-73
 in thrombocytopenic disorders, 65-66
 in thyroid disease, 71-72
 in toxoplasmosis, 67-68
 in varicella infection, 70

Umbilical cord occlusion, asphyxia in, 310

Urologic system, congenital anomalies of, in diabetic pregnancies, 519

Vagotomy model, of ARDS, 772

Varicella, umbilical blood sampling in, 70

Vasculopathy, in diabetic pregnancies, congenital anomalies and, 519-520
 intrauterine death and, 550

Vasodilators, in pulmonary hypertension, 137

Vasopressin, in labor initiation, 12

Vasopressors, in pulmonary hypertension, 136

Ventilation, mechanical, in pulmonary hypertension, 134-135
 surfactant therapy with, 750-752

Ventral wall defects, delivery route for, 94-97

Ventricular hypoplasia, in hypoplastic left heart syndrome, 145

Very low birth weight infants, handicapped, prevalence of, 263-277

Viral pneumonia, surfactants in, 775

Visual evoked potentials, in perinatal asphyxia, 451-461
 animal studies of, 454
 in full term infants, 456-458
 in preterm infants, 456
 vs. somatosensory evoked potentials, 458-459, 470-472

in respiratory distress syndrome (neonatal), 454-455

Vitamin A, as teratogen, 527

Vitamin E, in cerebral hypoxia-ischemia, 418

White classification, of diabetes mellitus, 514

Wilhelmy-Langmuir balance, in surfactant surface tension measurement, 669-671

Xanthine oxidase, in cerebral hypoxia-ischemia, 413-414

Yolk sac, hyperglycemia effects on, 521-522

Zidovudine (azidothymidine), in HIV infection, in pregnancy, 48-53

Zinc deficiency, congenital anomalies in, 527

